Meeting
2020 ASCO Virtual Scientific Program
Tumor-infiltrating lymphocytes and tumor budding refine prognostication in patients with low- and high-risk stage III colon cancers (NCCTG N0147)[Alliance].
Authors
Dan Sha
Mayo Clinic, Rochester, MN
Dan Sha , Hee Eun Lee , Nathan R. Foster , Qian Shi , Steven R Alberts , Thomas C. Smyrk , Frank A. Sinicrope
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Biologic Correlates
Citation
J Clin Oncol 38: 2020 (suppl; abstr 4065)
DOI
10.1200/JCO.2020.38.15_suppl.4065
Abstract #
4065
Poster Bd #
57
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Association of tumor infiltrating lymphocytes (TILs) with molecular subtype and prognosis in stage III colon cancers (CC) from a FOLFOX-based adjuvant chemotherapy trial.
First Author: Frank A. Sinicrope
Poster
2019 ASCO Annual Meeting
Relative contribution of clinical and molecular features to outcome within low and high risk T and N groups in stage III colon cancer (CC).
First Author: Frank A. Sinicrope
Poster
2019 ASCO Annual Meeting
Is the predictive and prognostic impact of sporadic and familial microsatellite instable stage III colon cancer different? A pooled analysis of the PETACC8 and NCCTG N0147 (Alliance) trials.
First Author: Aziz Zaanan
Poster
2017 ASCO Annual Meeting
Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status.
First Author: Julien Taieb